Analysts have been eager to weigh in on the Healthcare sector with new ratings on Halozyme (HALO – Research Report), Walgreens Boots Alliance ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its target price increased by equities research analysts at HC ...

Analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Axsome Therapeutics in a research note issued to investors on Thursday, February 20th. HC Wainwright analyst R ...

Leerink Partnrs lowered their FY2028 earnings per share estimates for Axsome Therapeutics in a research note issued on ...

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) shares hit a new 52-week high during trading on Friday after HC Wainwright raised their price target on the stock from $190.00 to $200.00. HC ...

William Blair cut their Q1 2025 earnings per share estimates for Axsome Therapeutics in a report issued on Tuesday, February ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price objective lifted by equities research analysts at Needham & Company LLC from $133.00 to $153.00 in a report released on ...

The U.S. FDA approved 12 drugs in January, falling below the 2024 monthly average of 19. Only three new molecular entities received approval, trailing the yearly average of just over four per month.

Axsome will grant Teva a license to sell its generic version of Auvelity beginning on or after March 31, 2039, if pediatric ...

Axsome's stock has risen 47% since my August recommendation, driven by FDA approvals and revenue growth. See why I maintain ...

H.C. Wainwright raised the firm’s price target on Axsome Therapeutics (AXSM) to $200 from $190 and keeps a Buy rating on the shares following ...